Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

836 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
Jiang N, Wang D, Hu Z, Shin HJ, Qian G, Rahman MA, Zhang H, Amin AR, Nannapaneni S, Wang X, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Ma J, Chen ZG, Saba NF. Jiang N, et al. Among authors: shin dm, shin hj. Mol Cancer Ther. 2014 Jul;13(7):1826-36. doi: 10.1158/1535-7163.MCT-13-1093. Epub 2014 Apr 18. Mol Cancer Ther. 2014. PMID: 24748655 Free PMC article.
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E Jr, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers J, Clayman G, Hong WK. Shin DM, et al. Cancer. 2002 Jul 15;95(2):322-30. doi: 10.1002/cncr.10661. Cancer. 2002. PMID: 12124833 Free article. Clinical Trial.
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G Jr, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. Herbst RS, et al. Among authors: shin dm. Cancer. 2002 Jul 15;95(2):340-53. doi: 10.1002/cncr.10629. Cancer. 2002. PMID: 12124835 Free article. Clinical Trial.
Advances in the management of malignant mesothelioma.
Khalil MY, Mapa M, Shin HJ, Shin DM. Khalil MY, et al. Among authors: shin dm, shin hj. Curr Oncol Rep. 2003 Jul;5(4):334-41. doi: 10.1007/s11912-003-0076-9. Curr Oncol Rep. 2003. PMID: 12781077 Review.
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Khuri FR, et al. Among authors: shin dm. Clin Cancer Res. 2004 May 1;10(9):2968-76. doi: 10.1158/1078-0432.ccr-03-0412. Clin Cancer Res. 2004. PMID: 15131032 Clinical Trial.
Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.
Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, Truong M, Moon H, Swisher SG, Fossella FV, Khuri FR, Hong WK, Shin DM. Kim ES, et al. Among authors: shin dm, shin hj. Lung Cancer. 2004 Jun;44(3):369-79. doi: 10.1016/j.lungcan.2003.12.010. Lung Cancer. 2004. PMID: 15140551 Clinical Trial.
Emerging drugs for head and neck cancer.
Rhee JC, Khuri FR, Shin DM. Rhee JC, et al. Among authors: shin dm. Expert Opin Emerg Drugs. 2004 May;9(1):91-104. doi: 10.1517/eoed.9.1.91.32953. Expert Opin Emerg Drugs. 2004. PMID: 15155138 Review.
836 results